Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
$359.26
-$0.58(-0.25%)
At close: 4:00 PM EST
$359.26
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$205.87 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.56M
Market Cap
$48.47B
Enterprise Value$62.68B
Total Cash (Recent Filing)$2.72B
Total Debt (Recent Filing)$2.77B
Price to Earnings (P/E)1494.4
Beta0.95
Next Earnings
Feb 12, 2026EPS Estimate
1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.84
Shares Outstanding132,113,820
10 Day Avg. Volume1,390,723
30 Day Avg. Volume1,557,552
Financial Highlights & Ratios
PEG Ratio2.84
Price to Book (P/B)447.73
Price to Sales (P/S)13.36
P/FCF Ratio-705.29
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue19.53
Enterprise Value/Gross Profit23.25
Enterprise Value/Ebitda336.00
Forecast
1Y Price Target
$501.06Price Target Upside39.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)7.94
Revenue Forecast (FY)$5.60B
Bulls Say, Bears Say
Bulls Say
Guidance And Sales OutlookCompany guidance exceeded analyst and consensus expectations for overall product sales and the transthyretin franchise, indicating stronger commercial momentum that could support upward revenue and valuation revisions.
Pipeline Clinical MilestonesMultiple upcoming clinical readouts across hereditary hemorrhagic telangiectasia, Huntington’s disease, and an adipose-targeting obesity program could materially de-risk the pipeline and act as meaningful catalysts if results are positive.
Strategic Roadmap And Platform ExpansionManagement unveiled a multi-year strategic roadmap committing substantial R&D investment and prioritizing leadership in transthyretin therapies while positioning a next-generation silencer with less frequent dosing as a key long-term growth driver.
Bears Say
Launch Momentum And Demand RiskData point to a slowing launch in the cardiomyopathy indication and seasonality or unexplained demand weakness could further pressure sales and investor confidence in franchise growth.
Near-term Revenue Surprise RiskReported transthyretin revenue came in below expectations, creating uncertainty about near-term patient uptake and increasing sensitivity to quarterly performance.
Profitability And Legal/Commercial RiskCompany margin targets are more modest than market expectations and combined risks from reimbursement, pricing pressure, potential dilution, and a government subpoena could raise expense assumptions and weigh on profitability.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $48.47B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 27 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $0.561 by $1.279.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.19.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 132,113,820 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.84 in its last earnings report, beating expectations of $0.561. Following the earnings report the stock price went down -6.651%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$501.06 (39.47% Upside)
$501.06 (39.47% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.0%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.53%
12-Months-Change
Fundamentals
Return on Equity
32.73%
Trailing 12-Months
Asset Growth
15.38%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the TTR franchise and strong pipeline advancements, with increased financial guidance indicating confidence in future performance. However, challenges remain with decreased gross margins and increased expenses, along with ongoing pricing negotiations in Europe.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$501.06
▲(39.47% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---